Inovio Biomedical Corp (NASDAQ:INO)

CAPS Rating: 2 out of 5

A biomedical company which deals in developing human applications of electroporation, which uses brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceuticals.

Results 1 - 20 of 40 : 1 2 Next »

Recs

1
Member Avatar zzlangerhans (99.78) Submitted: 4/5/2016 2:20:05 PM : Underperform Start Price: $9.88 INO Score: -5.06

I can't really claim that Inovio is a bogus biotech. After all, they've gotten VGX-3100 to the threshold of phase III and achieved reasonably significant deals with Roche and MedImmune. Nevertheless, I think 670M is a generous valuation in a shaky market for biotech given the company's long history of operations without any approved products and constantly-changing focus. Most of their current pipeline is in early stage trials and it will be a long time before the VGX-3100 phase III trial generates a significant catalyst. Cash of 183M is respectable but he quarterly burn is in the teens. This might not be an intuitive short but could be used as a counterweight for beloved long positions that are showing stretchmarks amid this spring sector rebound.

Recs

0
Member Avatar TomFoolNC (28.44) Submitted: 3/10/2016 3:07:51 PM : Underperform Start Price: $6.72 INO Score: -50.52

false run up due to non-existant zeke virus

Recs

0
Member Avatar adi101 (78.28) Submitted: 4/12/2015 6:13:50 AM : Outperform Start Price: $9.20 INO Score: +5.76

Find what are the attributes the Immune system latches on in an antigen (any Antigen – be it virus, bacteria, mushroom or a cancer cell), encode antigen production instructions in a RNA plasmid. Introduce into the body and let the cells themselves manufacture the part of the antigen. Let the Immune system discover the antigen and mount an immune reaction and you have immuned the body to this said antigen.
Now, use that platform to make the body produce monoclonal antibodies it needs as medicine, and heal itself.
Now use the platform to make the body make hormones it needs for as long as you design it.
Add management that is heavily invested and know how to bring non dilutive financing and behold – magic!

Recs

1
Member Avatar allstar31 (99.85) Submitted: 9/12/2014 10:58:34 PM : Underperform Start Price: $10.40 INO Score: +4.48

Uses known stock promoter Redchip.com, for a pump and dump scheme. Garbage.

Recs

0
Member Avatar Ronbo69 (< 20) Submitted: 7/22/2014 10:13:49 PM : Outperform Start Price: $13.87 INO Score: -29.17

How about a company with enough money to continue R&D work without any help from the big Pharma, Things are looking good going into results from Ph. II clinical, and with many other ongoing projects, eg. prostate research, things are very exciting.

Recs

0
Member Avatar kurdlingsvoice (< 20) Submitted: 6/12/2014 3:11:36 PM : Outperform Start Price: $8.79 INO Score: +11.27

Catalysts!

Recs

0
Member Avatar egnarops (26.45) Submitted: 6/11/2014 5:06:55 PM : Outperform Start Price: $8.82 INO Score: +11.55

Inovio is on the cusp of radically changing how we approach the treatment of cancer, malaria , all strains of flu, mers and many other deadly diseases .

Recs

0
Member Avatar Jared1048 (< 20) Submitted: 3/20/2014 3:50:38 PM : Outperform Start Price: $15.10 INO Score: -41.28

The product line up that they are going to come out with are second to none! Look into this company and you will soon see its extremely undervalued! checkout there expected earnings in 2017

Recs

1
Member Avatar ColossalSlug (< 20) Submitted: 3/13/2014 3:42:44 PM : Outperform Start Price: $13.64 INO Score: -35.30

Inovio has roughly a dozen vaccines in current trial that are very promising as indicated in previous studies. In addition to the keen abilities in R&D by some of the best researchers in the business, their partnerships are solid and will be extremely beneficial in the development and FDA application areas. The scope, success, and magnitude of what this company has in the pipeline - some with phase 2 trial results in 2014 - is just too hard to dismiss. Yes, investments in INO will be volatile and data driven, but we should be seeing fairly consistent stair-stepping to the upside for years to come.

Recs

0
Member Avatar SetMyPeopleFree (41.13) Submitted: 3/7/2014 12:08:32 PM : Outperform Start Price: $13.96 INO Score: -35.43

I bought a few hundred shares under $3, and added enough over 3 up to 3.55 to average $3. My biggest failure is not getting much more at $2.38 a couple weeks ago, or any at all on intra-day quick drop to $3 even last week. The science is mankind changing, and the CEO is not only genius in his field, but a Wharton MBA. This is a 10 bagger by next year, and perhaps a possible 500x even here near 3.50.

Recs

0
Member Avatar samuelbeh (< 20) Submitted: 2/20/2014 9:33:24 AM : Outperform Start Price: $11.44 INO Score: -21.79

Expecting positive results from clinical trials.

Recs

0
Member Avatar JungleDoctor (< 20) Submitted: 2/12/2014 11:59:15 PM : Outperform Start Price: $10.48 INO Score: -14.66

If malaria vaccine succeeds, will be a world changer

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 1/21/2014 3:24:16 AM : Outperform Start Price: $10.04 INO Score: -8.43

Flu play

Recs

0
Member Avatar jdowning22 (< 20) Submitted: 1/18/2014 8:06:56 PM : Outperform Start Price: $10.04 INO Score: -9.35

New drugs in the pipeline for quite awhile.

Recs

0
Member Avatar 98mmals (< 20) Submitted: 11/23/2013 7:35:31 PM : Outperform Start Price: $8.68 INO Score: +5.54

Important phase studies ending or ended and with crucial data coming out in the next 8 months that can blow up this stock like it did in Sept. when it ran to 3.00. New positive data will drive additional partnership talks, more funding, and more institutional buying

Recs

0
Member Avatar Brooer (< 20) Submitted: 11/17/2013 9:18:56 PM : Outperform Start Price: $7.96 INO Score: +15.84

Inovio recently made a deal with Roche Holdings AG for exclusive rights to just two of its many products still in early investigative stages.This deal could eventually be worth hundreds of millions and is only the first of what will hpoefully be many deals with big pharma in the near future.

Recs

0
Member Avatar remrem44 (< 20) Submitted: 8/5/2013 1:28:54 PM : Outperform Start Price: $5.00 INO Score: +85.51

5 in less 6 months

Recs

0
Member Avatar SAnitaB (< 20) Submitted: 8/2/2013 3:12:18 PM : Outperform Start Price: $8.14 INO Score: +6.49

Great trials results on several projects recently

Recs

0
Member Avatar stardog900 (< 20) Submitted: 7/27/2013 2:08:23 PM : Outperform Start Price: $6.00 INO Score: +50.45

If trials are successful, as is anticipated, this stock should outperform the S&P 500 over the next year or two.

Recs

2
Member Avatar whoodatstockhot (88.50) Submitted: 7/10/2013 12:31:40 PM : Outperform Start Price: $5.78 INO Score: +54.22

Pennvax-B trial extremely exciting, continued success will provide explosive upside. Nice risk/reward below $2.00. No secondary risk.

Results 1 - 20 of 40 : 1 2 Next »

Featured Broker Partners